The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
about
Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicineResistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivoHistone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinomaThe novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitroHistone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migrationHDAC inhibitors in kidney development and disease.Oxidative stress-induced epigenetic changes associated with malignant transformation of human kidney epithelial cells.The epigenetics of renal cell tumors: from biology to biomarkers.Potential biofluid markers and treatment targets for renal cell carcinoma.The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.New insights on chromatin modifiers and histone post-translational modifications in renal cell tumours.Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies.HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha.Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance.Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis.HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.Therapeutic effects of histone deacetylase inhibitors on kidney disease.Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.The epigenetic landscape of clear-cell renal cell carcinoma.
P2860
Q26779144-E057DBD6-AA2B-4152-AEC2-AD52606DF2B5Q28485252-905EA79F-4CF7-406A-A021-A848E048CDB4Q30251920-E447F9F9-84F5-4087-BC27-8969BCD85E08Q35022460-F9043CD1-CAF5-440E-B205-0F9CD586779DQ35052701-158CA5B5-A956-4EE0-AD89-F1C56D5396A4Q36230522-4AD62DA3-FC5B-4010-A6B0-B8C478F19D0DQ36608727-1F4F9EAA-D015-4ABF-A227-EEC884CF25C6Q37115414-4A51DDB0-CE5B-49B0-844E-B0E4D8A8C01DQ37706886-1C4E6FC9-5024-4FFE-B5C2-AE3FBBB7EE70Q38016153-DD3912E3-4440-4F77-9A3F-CAB99EB23883Q38094918-20002476-17DD-4D2D-8EDA-651E7CFC225CQ38095611-9572101A-160F-497C-8960-8F51A07FA598Q38294198-30A51125-76F6-4494-AD53-800C3F618B1EQ38819408-C723618C-C7F5-4721-81F0-0AA78B372A8EQ38984146-227C5CEB-CB0A-44E2-ACDB-18A6EC7D0686Q39369865-7B89CF4F-B191-4C0B-AD5F-0B2D6FBB949DQ39678597-D1065424-F0C0-466E-85B0-3F01A2234AC2Q39907173-D091A46A-0290-4793-82EE-1466CA75D586Q41203569-AD9C5276-C0F1-4BFB-B5E5-0396C60B5D27Q41574276-C0FBF877-50EA-4931-B829-1A15844095CCQ42571975-4D801C01-3D0C-40F7-92B5-B099A8FF3024Q47100939-7CCA6C86-F0AB-465F-AEC3-F48B6A477636Q48136812-7A26CF2E-C3AC-4913-836A-73095AC7C3A8Q49849134-21883C30-7529-4A5E-855B-2D3113382AE1Q51091490-2E59A82C-4DF9-4D5E-8067-9D26719D2E6C
P2860
The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
The histone deacetylase inhibi ...... arcinoma in vitro and in vivo.
@en
The histone deacetylase inhibi ...... arcinoma in vitro and in vivo.
@nl
type
label
The histone deacetylase inhibi ...... arcinoma in vitro and in vivo.
@en
The histone deacetylase inhibi ...... arcinoma in vitro and in vivo.
@nl
prefLabel
The histone deacetylase inhibi ...... arcinoma in vitro and in vivo.
@en
The histone deacetylase inhibi ...... arcinoma in vitro and in vivo.
@nl
P2093
P2860
P1476
The histone deacetylase inhibi ...... carcinoma in vitro and in vivo
@en
P2093
Ausra Mickuckyte
Dietger Jonas
Eva Juengel
Lukasz Hudak
Roman A Blaheta
Steffen Wedel
P2860
P304
P356
10.1111/J.1582-4934.2008.00436.X
P577
2008-07-24T00:00:00Z